TCEA3_HUMAN: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Target Name: TCEA3

NCBI ID: G6920

TCEA3

TCEA3_HUMAN: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Abstract:

Chronic pain is a significant public health issue that affects millions of individuals worldwide. The pain caused by chronic diseases such as cancer, diabetes, and rheumatoid arthritis can lead to significant morbidity and quality of life. The development of new treatments for chronic pain remains a major goal in the field of medicine. TCEA3_HUMAN is a promising drug target and biomarker that has been identified as a potential drug target for the treatment of chronic pain. This article will discuss the mechanism of TCEA3_HUMAN, its potential as a drug target, and its potential as a biomarker for the diagnosis and treatment of chronic pain.

Introduction:

Chronic pain is a persistent and often debilitating condition that can be caused by a variety of factors, including cancer, diabetes, rheumatoid arthritis, and other chronic diseases. According to the World Health Organization (WHO), chronic pain affects over 120 million people worldwide, with 95% of the population experiencing chronic pain. Chronic pain can cause significant morbidity, decreased quality of life, and economic burden.

The development of new treatments for chronic pain remains a major goal in the field of medicine. While several drugs have been developed and are currently used to treat chronic pain, the majority of these drugs have limited efficacy and potential for long-term treatment. The development of new treatments for chronic pain requires the identification of new drug targets and biomarkers.

TCEA3_HUMAN: A Potential Drug Target

TCEA3 (T-cell engulfed antigen 3) is a protein that is expressed in a variety of tissues and cells, including the brain, spinal cord, and gastrointestinal tract. TCEA3 has been shown to play a role in the immune response and has been implicated in the development of several chronic diseases, including cancer and rheumatoid arthritis.

Recent studies have suggested that TCEA3 may have potential as a drug target for the treatment of chronic pain. TCEA3 has been shown to interact with several pain modulators, including opioids and nonsteroidal anti-inflammatory drugs (NSAIDs). TCEA3 has also been shown to modulate the activity of several pain-related genes, including those involved in neuroinflammation and pain processing.

TCEA3 has been shown to have anti-inflammatory effects, which may help to reduce the persistent pain caused by chronic diseases. Additionally, TCEA3 has been shown to have neuroprotective effects, which may help to prevent the development of neurodegenerative diseases.

TCEA3_HUMAN: A Potential Biomarker

The development of new biomarkers for the diagnosis and treatment of chronic pain remains a major goal in the field of medicine. TCEA3_HUMAN may be a promising biomarker for the diagnosis and treatment of chronic pain.

TCEA3_HUMAN has been shown to be expressed in several tissues and cells, including the brain, spinal cord, and gastrointestinal tract. This suggests that TCEA3_HUMAN may be a useful biomarker for the diagnosis of chronic pain. Additionally, TCEA3_HUMAN has been shown to interact with several pain modulators, including opioids and NSAIDs. This suggests that TCEA3_HUMAN may be a useful biomarker for the treatment of chronic pain.

Molecular Mechanisms:

The molecular mechanisms underlying the development and maintenance of chronic pain are not fully understood. However, several studies have suggested that chronic pain is caused

Protein Name: Transcription Elongation Factor A3

Functions: Necessary for efficient RNA polymerase II transcription elongation past template-encoded arresting sites. The arresting sites in DNA have the property of trapping a certain fraction of elongating RNA polymerases that pass through, resulting in locked ternary complexes. Cleavage of the nascent transcript by S-II allows the resumption of elongation from the new 3'-terminus

The "TCEA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TCEA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets